The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 123.50, with a high estimate of 207.00 and a low estimate of 50.00. The median estimate represents a +128.87% increase from the last price of 53.96.
The current consensus among 27 polled investment analysts is to Buy stock in Intellia Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.29
Reporting Date Nov 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.